Ascletis’ rival to Lilly’s Foundayo hits diabetes trial goals
Ascletis’ rival to Lilly’s Foundayo hits diabetes trial goals
Ascletis Pharma
HKEX: 1672 ~$0.5B (HKEX, small-cap) MCAP
Ascletis Pharma is a China-based clinical-stage biopharmaceutical company developing small-molecule and peptide therapeutics for viral diseases, metabolic diseases (including obesity), and oncology. Its lead metabolic candidate ASC36_35 FDC targets GLP-1/GIP agonism.
Company Info
Recent News
Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting
Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting.